Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care
Open accessThe DOI matches its Crossref record; 83 of the 87 references it cites were found in a registry or an index; 53 of the 80 sources its claims cite were checked for support.
Abstract
The available data suggest differences in the course of type 2 diabetes mellitus (T2DM) between men and women, influenced by the distinguishing features of the sex. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a relatively new class of antidiabetic drugs that act by mimicking the function of endogenous glucagon-like peptide 1. They constitute valuable agents for the management of T2DM as, in addition to exerting a strong hypoglycemic action, they present cardiorenal protective properties, promote weight loss, and have a good safety profile, particularly with respect to the risk of hypoglycemia. Due to the precedent of studies having identified sexual dimorphic elements regarding the action of other antidiabetic agents, ongoing research has attempted to examine whether this is also the case for GLP-1 RAs. Until now, sex differences have been observed in the impact of GLP1-RAs on glycemic control, weight reduction, and frequency of adverse events. On the contrary, the question of whether these drugs differentially affect the two sexes with respect to cardiovascular risk and incidence of major adverse cardiovascular events remains under investigation. Knowledge of the potential sex-specific effects of these medications is extremely useful for the implementation of individualized therapeutic plans in the treatment of T2DM. This narrative review aims to present the available data regarding the sex-specific action of GLP-1 RAs as well as to discuss the potential pathophysiologic mechanisms explaining these dissimilarities.
Overview
CoChat Summary
TL;DR
This narrative review examines whether biological sex modifies the efficacy and safety of GLP-1 receptor agonists in type 2 diabetes and obesity. It concludes that women tend to achieve greater weight loss and report more gastrointestinal adverse events, while sex differences in glycemic control and cardiovascular outcomes remain inconsistent and under-investigated.
Key findings
- Weight loss appears more pronounced in women across several studies: e.g., −7.0 kg vs. −3.3 kg in a retrospective study (p < 0.06); 33% of women vs. 17% of men achieved weight-loss targets after 12 months of exenatide; BMI reduction 4.8 vs. 2.6 kg/m² (p < 0.05); dulaglutide −1.32 kg in females (p = 0.001) vs. +0.09 kg in males (p < 0.001). Liraglutide exposure was 32% higher in women than men of comparable weight.
- Glycemic efficacy findings are mixed. Some analyses show no sex effect (dulaglutide HbA1c reduction −1.26% in men vs. −1.33% in women; post hoc analysis of 855 patients), while others favor women (exenatide plus metformin reduced HbA1c from 8.8% to 6.8% in women vs. 8.9% to 7.5% in men, p < 0.05; metformin plus liraglutide −1.5 vs. −0.75, p = 0.028) or men (38% vs. 27% achieved HbA1c ≤7% with exenatide twice daily, p = 0.03; male sex predicted treatment failure, OR 2.55).
- Women report more adverse events, especially gastrointestinal: dulaglutide 86.5% of women vs. 61.4% of men; liraglutide 83.3% vs. 65.5%. A Korean database analysis found women about twice as likely to report any adverse event (reporting ratio 2.34) and higher headache risk (risk ratio 7.97). No significant sex difference was found for nocturnal or total hypoglycemia.
- Cardiovascular and MACE findings are inconclusive: some studies show no sex divergence (hazard ratio 0.88 in both sexes; meta-analysis p = 0.375), while one study found lower MACE incidence in women (6.6 vs. 11.9 per 1000 person-years, p < 0.001) and a greater risk reduction with GLP-1 RAs vs. sulfonylureas in women (adjusted HR 0.57 vs. 0.82, p = 0.001). Effects on waist circumference, blood pressure, and lipids remain uncertain.
Methods
- Design: narrative review of available data on sex-specific actions of GLP-1 RAs in type 2 diabetes and obesity.
- Data: synthesized evidence from clinical trials, pooled and post hoc analyses, retrospective and cohort studies, meta-analyses, pharmacokinetic/exposure analyses, and animal studies.
- Analysis: narrative synthesis, with tables summarizing drug characteristics, exposure/dose–effectiveness–adverse event relationships, and sex differences. No systematic search strategy or meta-analysis is described.
Limitations
- Stated by the authors: most referenced studies have heterogeneous patient populations differing in diabetes duration, pharmacologic regimen, and prior medication history; most studies examining sex effects are post hoc analyses with secondary outcomes; and many studies lack sex-disaggregated data.
- Evident from the text: as a narrative review, it does not describe a systematic search, quality appraisal, or quantitative synthesis; findings across studies are conflicting, and only a small number of studies stratified cardiovascular outcomes by sex.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
49 Valid · 6 Not valid · 21 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In male mice, specific upregulated DEGs were associated with mitochondrial function, which is known to affect the process of insulin secretion.”
§ Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care > 5. Discussion
What the sources say
- Disputedcites [84] Liu, 2021, Single-cell RNA Sequencing Reveals Sexually Dimorphic Transcriptome and Type 2 Diabetes Genes in Mouse Islet β Cells, Genom. Proteom. Bioinform. sourceExperimental — accuracy not yet measured
In Results (‘Extensive sex-dependent T2D gene expression alterations in mouse β cells’; page unavailable), the paper identifies the mitochondrial-function genes Cox4i1 and Ndufb7 as down-regulated in β cells of male T2D mice, contrary to the claim that they were upregulated. The same passage does associate mitochondrial function with insulin secretion capacity. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The pathophysiology of these sex-specific differences is to a great extent hormonally regulated, with estrogen playing a key role in the disease process in females [13].”
§ Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care > 1. Introduction
What the sources say
- Partly supportedcites [13] Arnetz, 2014, Sex differences in type 2 diabetes: Focus on disease course and outcomes, Diabetes Metab. Syndr. Obes. Targets Ther. sourceExperimental — accuracy not yet measured
The sections on hormonal pathophysiology and estrogen describe sex-related hormonal effects on glycemic control, including an association between declining estrogen after menopause and increased risk of elevated fasting plasma glucose. But the Introduction says the reasons for sex differences remain unclear and lists other possible contributors; the paper does not establish that they are to a great extent hormonally regulated. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Studies that used different representatives of the class, such as dulaglutide and liraglutide, have generated similar findings [50,57].”
§ Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care > 3. Sex-Specific Efficacy of GLP-1 RAs > 3.2. Weight Loss
What the sources say
- Supportedcites [50] Gallwitz, 2018, Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c, Diabetes Obes. Metab. source
For the dulaglutide part of the multi-citation sentence, the Discussion reports that women had numerically greater weight loss or less weight gain than men in the majority of studies. The paper does not establish a statistically significant sex difference in weight loss. (LLM, conf=0.88)
- Supportedcites [57] Onishi, 2017, Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan, Endocr. J. source
The Efficacy section reports numerically greater weight loss in females than males treated with either dulaglutide or liraglutide in the analyzed Japanese patients with type 2 diabetes. The Discussion likewise states that females treated with both drugs had greater mean weight loss. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Due to the relatively recent authorization for clinical use for the treatment of T2DM, the sex-specific properties of these agents have not been adequately investigated [21,22].”
§ Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [21] Pencek, 2012, Exenatide Twice Daily: Analysis of Effectiveness and Safety Data Stratified by Age, Sex, Race, Duration of Diabetes, and Body Mass Index, Postgrad. Med. source
- Supportedcites [22] Anichini, 2013, Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: A real world experience, Diabetes Metab. Syndr. Obes. source
The Introduction says data on gender differences in routine exenatide use are scarce. The Discussion adds that few clinical studies have specifically investigated gender differences in therapy with GLP-1 receptor agonists, supporting the claim that their sex-specific clinical effects remain insufficiently studied. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similar results were presented in another cohort study in which after a 12-month period of exenatide treatment, 33% of women achieved weight loss targets compared to 17% of men [22].”
§ Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care > 3. Sex-Specific Efficacy of GLP-1 RAs > 3.2. Weight Loss
What the sources say
- Supportedcites [22] Anichini, 2013, Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: A real world experience, Diabetes Metab. Syndr. Obes. source
The Results report that at 12 months, 33% of women versus 17% of men achieved the study’s target weight loss. Patients and methods describes a cohort treated with exenatide and followed for 12 months. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
55 more claims · 27 with their cited sources checked
Create a free account to see all 103 claims and to verify the 3 references still open.
- It may state two separate claims as one. 35
- Probably not a substantial claim. 11
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Adverse effects also differ: women report higher rates of gastrointestinal intolerance (nausea, vomiting, cholelithiasis) with incretin-based therapies, likely due to estrogen’s effects on biliary motility [182].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [182]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Given that GI AEs occur more commonly in females than in males, the sex-related differences in GI AEs may offer an additional framework to explain the increased efficacy of these drugs among women, independently from the level of exposure ([76]; and references therein).”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [76]
The cited source says what the claim attributes to it.
In the citing paper
“Given that GI AEs occur more commonly in females than in males, the sex-related differences in GI AEs may offer an additional framework to explain the increased efficacy of these drugs among women, independently from the level of exposure ([76]; and references therein).”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [76]
The cited source says what the claim attributes to it.
In the citing paper
“Obesity and T2D are characterized by sexual dimorphism, which appears to be an important determinant of presentation, diagnosis, disease progression and complications, and, therefore, may be important for individual treatment approaches ([76,77,78]; and references therein).”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [76]
The cited source says what the claim attributes to it.
In the citing paper
“Although the different GLP-1 RAs do not allow the same results to be achieved in terms of weight loss, cumulative evidence suggests that, even by using different representatives of this class, weight reduction is similarly more pronounced in females than in males ([76]; and references therein).”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [76]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care > 3. Sex-Specific Efficacy of GLP-1 RAs > 3.1. Hypoglycemic Efficacy
“HbA1c target (≤7% or 53 mmol/mL)”
§ Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care > 3. Sex-Specific Efficacy of GLP-1 RAs > 3.1. Hypoglycemic Efficacy
“HbA1c levels < 7% (<53 mmol/mol)”
Citations
Cites
Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus
Kautzky-Willer, A., Harreiter, J., & Pacini, G. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1137 · Cited by 2,043
The Pathophysiology of Gestational Diabetes Mellitus
Plows, J. F., Stanley, J. L., Baker, P. N., Reynolds, C. M., & Vickers, M. H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113342 · Cited by 1,874 · cited 1×
“However, in an individual with pre-existing β-cell dysfunction this process of adaptation is not possible and therefore a hyperglycemic state occurs [19].”
BackgroundThe role of estrogens in control of energy balance and glucose homeostasis
Mauvais-Jarvis, F., Clegg, D. J., & Hevener, A. L. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1055 · Cited by 1,329
Leon, B. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i13.1246 · Cited by 1,215
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s006 · Cited by 847
Direct effects of sex steroid hormones on adipose tissues and obesity
Mayes, J. S., & Watson, G. H. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00152.x · Cited by 508
Kolterman, O. G., Kim, D. D., Shen, L., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. D. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.2.173 · Cited by 434
Determinants of Adherence to Diabetes Medications: Findings From a Large Pharmacy Claims Database
Kirkman, M. S., Rowan-Martin, M. T., Levin, R., Fonseca, V. A., Schmittdiel, J. A., Herman, W. H., & Aubert, R. E. (2015) · Diabetes Care · doi:10.2337/dc14-2098 · Cited by 388
Gender differences in glucose homeostasis and diabetes
Mauvais-Jarvis, F. (2018) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.08.016 · Cited by 377 · cited 2×
“More specifically, it has been argued that testosterone deficiency may be responsible for insulin resistance in males, whereas in females the latter can occur as a result of a hyperandrogenic state [14].”
Background
Research works printed but not linked: 5
- (2022, February 28). PubChem Exenatide, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/45588096.
- (2022, February 28). PubChem Liraglutide, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/16134956.
- (2022, February 28). PubChem Albiglutide, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/145994868.
- (2022, February 28). PubChem Lixisenatide, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/90472060.
- (2022, February 28). PubChem Semaglutide, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/56843331.
Cited by
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
Butler, J., Shah, S. J., Petrie, M. C., Borlaug, B. A., Abildstrøm, S. Z., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Verma, S., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00469-0 · Cited by 386
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148
GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans
Kim, K. S., Park, J. S., Hwang, E., Park, M. J., Shin, H. Y., Lee, Y. H., Kim, K. M., Gautron, L., Godschall, E., Portillo, B., et al. (2024) · Science · doi:10.1126/science.adj2537 · Cited by 148
Sex-based differences in insulin resistance
Gado, M., Tsaousidou, E., Bornstein, S. R., & Perakakis, N. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0245 · Cited by 138
Metadata
- Authors
- Rentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K.
- Affiliations
- Aristotle University of Thessaloniki (GR)
- Corresponding author
- Kotsa, Kalliopi
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2022-03-13
- Volume
- 12
- Issue
- 3
- Pages
- 454
- ISSN
- 2075-4426 (ISSN-L)
- PMC
- PMC8950819
- OpenAlex
- W4221056231
- Cited by
- 140
- References
- 87
- Citations by year
- 2026: 35 · 2025: 44 · 2024: 40 · 2023: 17 · 2022: 4
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Personalized Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Sex and Gender in Healthcare
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- sex differences, GLP-1 receptor agonists, type 2 diabetes, obesity, glycemic control, weight loss, major adverse cardiovascular events, cardiorenal protection, adverse drug reactions, personalized medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care. https://app.cochat.ai/papers/10.3390/jpm12030454
- The paper
- Rentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K. (2022). Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care. Journal of Personalized Medicine. https://doi.org/10.3390/jpm12030454
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
